Lung Cancer in the Context of a Precision Medicine Approach

Efforts Aim to Make Clinical Trial Information More Accessible

Drug Approval Processes Around the World: Focus on China

Impact of Clinical Pathways on Lung Cancer Management

PD-L1 Blueprint Project

Drug Development in the 21st Century

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A New Paradigm Post-IASLC WCLC 2016

NICE: It Takes Two to Tango

What’s New from the 2016 ESMO Clinical Guidelines

The Lung Master Protocol (Lung-MAP)

Changing Landscape of Front-line Immunotherapy

Update to the “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors”